Expanded access programs open a potential path to investigational treatments that can help manage your disease and support ...
AUSTIN, Texas--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the response from a Type C meeting with the U.S. Food and Drug Administration (FDA) ...
Program Enables Physicians to Request Molgramostim for Eligible Patients in Select Geographies Where the Product is Not Commercially Available and in Compliance with Local Regulatory Requirements ...
LANGHORNE, Pa. - Savara Inc. (NASDAQ:SVRA), a biopharmaceutical company specializing in rare respiratory diseases, announced the initiation of an Expanded Access Program (EAP) for molgramostim, ...
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the response from a Type C meeting with the U.S. Food and Drug Administration (FDA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results